Clinical data | |
---|---|
Other names | TAT-59; Iproxifene |
Routes of administration | Oral |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C29H36NO5P |
Molar mass | 509.583 g·mol−1 |
3D model (JSmol) | |
| |
|
Miproxifene phosphate (former developmental code name TAT-59) is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group[1] that was under development in Japan for the treatment of breast cancer but was abandoned and never marketed.[2][3][4][5] It reached phase III clinical trials for this indication before development was discontinued.[2][5] The drug is a phosphate ester and prodrug of miproxifene (DP-TAT-59) with improved water solubility that was better suited for clinical development.[2][3][6][7] Miproxifene has been found to be 3- to 10-fold as potent as tamoxifen in inhibiting breast cancer cell growth in in vitro models.[2][5][4] It is a derivative of afimoxifene (4-hydroxytamoxifen) in which an additional 4-isopropyl group is present in the β-phenyl ring.[8]